Natural Products as Farnesoid X Receptor (FXR) Agonists: Their Interactions with FXR Ligand Binding Region

被引:0
|
作者
Lin, Hsiang-Ru [1 ]
机构
[1] Natl Kaohsiung Normal Univ, Coll Sci, Dept Chem, Kaohsiung 82446, Taiwan
关键词
Farnesoid X receptor (FXR); FXR ligand binding region; liver; NAFLD; nuclear receptors; natural product; NUCLEAR RECEPTOR; NONALCOHOLIC STEATOHEPATITIS; CRYPTOCARYA-CHINENSIS; METABOLISM; ACTIVATION; IDENTIFICATION; TRITERPENES; EXPRESSION; ACT;
D O I
10.2174/1570193X13666160401000445
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
Nuclear receptors (NRs) are ligand-activated transcription factors modulating significant biological functions including cell growth, lipid metabolism, and glucose homeostasis, so they are frequently to be utilized as important drug targets to develop therapeutic reagents. Farnesoid X receptor (FXR) with bile acids as the natural ligands, plays an essential role in regulation of bile acid and glucose metabolism, and is involved in the pathologies of human diseases including diabetes and chronic liver diseases. Thus, FXR is a promising pharmacological target for these diseases. Synthetic FXR agonists like INT-747 developed by Intercept Pharmaceutical Company is in the clinical trial phase III for non-alcoholic steatohepatitis and can be approved as the treatment of primary biliary cirrhosis in 2016. Due to the promising clinical trial results of INT-747, the naturally occurring FXR ligands may be utilized as the preventive nutraceuticals or treatments of the chronic liver diseases and diabetes. In this review, the natural FXR agonists are summarized and their possible interactions with FXR ligand binding region are discussed.
引用
收藏
页码:97 / 108
页数:12
相关论文
共 50 条
  • [21] Farnesoid X receptor (FXR) regulates peripheral insulin sensitivity
    Cariou, B
    Duran-Sandoval, D
    van Harmelen, K
    van Dijk, TD
    Bouchaert, E
    Fruchart, JC
    Kuipers, F
    Staels, B
    DIABETOLOGIA, 2005, 48 : A206 - A206
  • [22] The farnesoid X receptor (FXR) as modulator of bile acid metabolism
    Kuipers, F
    Claudel, T
    Sturm, E
    Staels, B
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2004, 5 (04): : 319 - 326
  • [23] The Farnesoid X Receptor (FXR) as Modulator of Bile Acid Metabolism
    Folkert Kuipers
    Thierry Claudel
    Ekkehard Sturm
    Bart Staels
    Reviews in Endocrine and Metabolic Disorders, 2004, 5 : 319 - 326
  • [24] The current and future medical treatment of NASH: from vitamin E to Farnesoid X Receptor (FXR) agonists
    Younossi, Z. M.
    JOURNAL OF VIRAL HEPATITIS, 2015, 22 : 10 - 11
  • [25] Medicinal Chemistry and Pharmacological Effects of Farnesoid X Receptor (FXR) Antagonists
    Lamers, Christina
    Schubert-Zsilavecz, Manfred
    Merk, Daniel
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2014, 14 (19) : 2188 - 2205
  • [26] Role of Farnesoid X Receptor (FXR) in control of plasma lipid levels
    Claudel, T
    Elzinga, BM
    Bloks, V
    Staels, B
    Voshol, PJ
    Kuipers, F
    ATHEROSCLEROSIS SUPPLEMENTS, 2005, 6 (01) : 95 - 96
  • [27] Regulation of the farnesoid X receptor (FXR) by bile acid flux in rabbits
    Xu, GR
    Pan, LX
    Li, H
    Forman, BM
    Erickson, SK
    Shefer, S
    Bollineni, J
    Batta, AK
    Christie, J
    Wang, TH
    Michel, J
    Yang, S
    Tsai, R
    Lai, L
    Shimada, K
    Tint, GS
    Salen, G
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (52) : 50491 - 50496
  • [28] a Farnesoid-X-Receptor (FXR)-Glucocorticoid Receptor (GR) Cascade Regulates Intestinal Innate Immunity in Response to FXR Activation
    Renga, Barbara
    Mencarelli, Andrea
    D'Amore, Claudio
    Zampella, Angela
    Distrutti, Eleonora
    Fiorucci, Stefano
    GASTROENTEROLOGY, 2012, 142 (05) : S878 - S878
  • [29] Farnesoid-X Receptor (FXR) as a Promising Pharmaceutical Target in Atherosclerosis
    Moris, Demetrios
    Giaginis, Constantinos
    Tsourouflis, Gerasimos
    Theocharis, Stamatios
    CURRENT MEDICINAL CHEMISTRY, 2017, 24 (11) : 1147 - 1157
  • [30] Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR)
    Merk, Daniel
    Gabler, Matthias
    Gomez, Roberto Carrasco
    Flesch, Daniel
    Hanke, Thomas
    Kaiser, Astrid
    Lamers, Christina
    Werz, Oliver
    Schneider, Gisbert
    Schubert-Zsilavecz, Manfred
    BIOORGANIC & MEDICINAL CHEMISTRY, 2014, 22 (08) : 2447 - 2460